Welcome to our dedicated page for Akari Therapeutics Plc SEC filings (Ticker: AKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering whether nomacopan hit its clinical endpoints or how much cash Akari has left to fund trials? Investors comb Akari Therapeutics filings for exactly these answers. From fresh Phase II data tucked into an 8-K to detailed R&D spend in the quarterly 10-Q, each document shapes the outlook for this orphan-disease biotech.
Stock Titan keeps every disclosure in one place and makes them readable. Our AI converts the 200-page annual report into plain language, surfaces section-by-section highlights, and links directly to the numbers you need. Searching for “Akari Therapeutics insider trading Form 4 transactions” or real-time alerts on executive stock moves? We tag each Form 4 the moment it hits EDGAR and show patterns across time. Need the “Akari Therapeutics quarterly earnings report 10-Q filing” or an “Akari Therapeutics proxy statement executive compensation” breakdown? One click delivers AI-generated context alongside the original PDF.
- Track trial milestones via “Akari Therapeutics 8-K material events explained”
- Get cash-runway metrics from the latest “Akari Therapeutics earnings report filing analysis”
- Receive instant alerts on “Akari Therapeutics Form 4 insider transactions real-time”
Whether you’re understanding Akari Therapeutics SEC documents with AI or need the “Akari Therapeutics annual report 10-K simplified”, our platform delivers clarity. Stop downloading bulky files; start focusing on the clinical and financial signals that move AKTX.
Insider Trading Alert: Abizer Gaslightwala, President & CEO and Director of Akari Therapeutics, has increased his position through two separate purchases of American Depositary Shares (ADS):
- June 23, 2025: Acquired 943 ADS at $1.15 per share
- June 24, 2025: Acquired 5,203 ADS at weighted average price of $1.16
Following these transactions, Gaslightwala now directly owns 277,574 ADS. Each ADS represents 2,000 ordinary shares with $0.0001 par value. The insider's accumulation of shares at these price levels may signal management's confidence in the company's prospects. The Form 4 was filed within the required reporting timeframe and executed by Torsten Hombeck as Attorney-in-Fact.
Akari Therapeutics plc (NASDAQ: AKTX) – Form 4 insider transaction
On 06/20/2025, President & Chief Executive Officer Abizer Gaslightwala, who also serves as a director of the company, purchased 10,000 American Depositary Shares (ADS) of Akari Therapeutics in an open-market transaction. The shares were acquired at a price of $1.20 per ADS, for an aggregate consideration of approximately $12,000.
Following the purchase, the reporting person’s direct holding increased to 271,428 ADS. Each ADS represents 2,000 ordinary shares of Akari Therapeutics with a par value of $0.0001 per ordinary share, as noted in the footnote to the filing.
No dispositions were reported, and the filing shows no derivative security transactions. The form was signed by Torsten Hombeck, acting as attorney-in-fact, on 06/24/2025.
This Form 4 therefore documents a single, straightforward insider purchase by the company’s most senior executive, with no accompanying sales or option exercises disclosed.
Insider Purchase Alert: Abizer Gaslightwala, President & CEO and Director of Akari Therapeutics, has acquired 15,000 American Depositary Shares (ADS) at a price of $1.20 per share on June 17, 2025. Each ADS represents 2,000 ordinary shares of the company.
Following this transaction, Gaslightwala now beneficially owns 261,428 ADSs directly. This insider purchase demonstrates a significant investment by the company's top executive, potentially signaling confidence in the company's future prospects.
- Transaction Type: Direct Purchase (Form 4)
- Total Investment Value: $18,000
- Transaction Date: June 17, 2025
- Filing Date: June 28, 2025
- Ownership Form: Direct
FAQ
What is the current stock price of Akari Therapeutics Plc (AKTX)?
What is the market cap of Akari Therapeutics Plc (AKTX)?
What is the core focus of Akari Therapeutics?
Which pathways does Akari Therapeutics target in its drug development?
How does Akari's lead compound function?
What differentiates Akari Therapeutics from other biotechnology companies?
What are the primary product candidates in Akari’s pipeline?
Who benefits from the therapies developed by Akari Therapeutics?
